SG11201602826VA - Icotinib-containing topical skin pharmaceutical compositions and uses thereof - Google Patents
Icotinib-containing topical skin pharmaceutical compositions and uses thereofInfo
- Publication number
- SG11201602826VA SG11201602826VA SG11201602826VA SG11201602826VA SG11201602826VA SG 11201602826V A SG11201602826V A SG 11201602826VA SG 11201602826V A SG11201602826V A SG 11201602826VA SG 11201602826V A SG11201602826V A SG 11201602826VA SG 11201602826V A SG11201602826V A SG 11201602826VA
- Authority
- SG
- Singapore
- Prior art keywords
- icotinib
- pharmaceutical compositions
- topical skin
- containing topical
- skin pharmaceutical
- Prior art date
Links
- QQLKULDARVNMAL-UHFFFAOYSA-N icotinib Chemical compound C#CC1=CC=CC(NC=2C3=CC=4OCCOCCOCCOC=4C=C3N=CN=2)=C1 QQLKULDARVNMAL-UHFFFAOYSA-N 0.000 title 1
- 229950007440 icotinib Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000000699 topical effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013085042 | 2013-10-11 | ||
| PCT/CN2014/088344 WO2015051763A1 (zh) | 2013-10-11 | 2014-10-11 | 一种含埃克替尼的皮肤外用药物组合物及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201602826VA true SG11201602826VA (en) | 2016-05-30 |
Family
ID=52812537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201602826VA SG11201602826VA (en) | 2013-10-11 | 2014-10-11 | Icotinib-containing topical skin pharmaceutical compositions and uses thereof |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20160235757A1 (https=) |
| EP (1) | EP3056206A4 (https=) |
| JP (1) | JP6463745B2 (https=) |
| AU (1) | AU2014334222B2 (https=) |
| BR (1) | BR112016007627A2 (https=) |
| CA (1) | CA2926874C (https=) |
| HK (1) | HK1213813A1 (https=) |
| IL (1) | IL245015A0 (https=) |
| NZ (1) | NZ718802A (https=) |
| RU (1) | RU2698796C2 (https=) |
| SG (1) | SG11201602826VA (https=) |
| TW (1) | TWI630921B (https=) |
| WO (1) | WO2015051763A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102270538B1 (ko) * | 2013-06-09 | 2021-06-29 | 베타 파머수티컬 컴퍼니 리미티드 | 이코티닙 포스페이트의 신규한 다형체 형태 및 이의 용도 |
| WO2022022434A1 (zh) * | 2020-07-27 | 2022-02-03 | 杭州和正医药有限公司 | 含托法替尼药学上可接受的盐的药物组合物、制剂及应用 |
| CN116829152A (zh) * | 2021-02-02 | 2023-09-29 | 贝达药业股份有限公司 | 埃克替尼在非小细胞肺癌术后辅助治疗中的应用 |
| CN116492293A (zh) * | 2022-01-25 | 2023-07-28 | 杭州和正医药有限公司 | 一种含托法替尼的局部用药的药物组合物、制剂及应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0618933A2 (pt) * | 2005-11-24 | 2016-09-13 | Basf Se | método para produzir uma molécula efetora que se liga à queratina, molécula efetora que se liga à queratina, uso das moléculas efetoras que se ligam à queratina, composto, e, dermocosmético |
| FR2909284B1 (fr) * | 2006-11-30 | 2012-09-21 | Galderma Sa | Nouvelles compositions sous forme d'onguent sans vaseline comprenant un derive de vitamine d et eventuellement un anti-inflammatoire steroidien |
| EP2392576B1 (en) | 2008-07-08 | 2016-02-17 | Beta Pharma, Inc. | Icotinib hydrochloride, synthesis, crystallographic form, medical combination, and uses thereof |
| GB201010954D0 (en) * | 2010-06-29 | 2010-08-11 | Edko Pazarlama Tanitim Ticaret | Compositions |
| MX2013004296A (es) * | 2010-10-21 | 2013-09-26 | Cadila Healthcare Ltd | Composiciones farmaceuticas topicas que contienen gotas de tamaño nanometrico para el tratamiento de soriasis. |
-
2014
- 2014-10-11 SG SG11201602826VA patent/SG11201602826VA/en unknown
- 2014-10-11 WO PCT/CN2014/088344 patent/WO2015051763A1/zh not_active Ceased
- 2014-10-11 US US15/028,118 patent/US20160235757A1/en not_active Abandoned
- 2014-10-11 AU AU2014334222A patent/AU2014334222B2/en not_active Ceased
- 2014-10-11 RU RU2016118063A patent/RU2698796C2/ru not_active IP Right Cessation
- 2014-10-11 BR BR112016007627A patent/BR112016007627A2/pt not_active IP Right Cessation
- 2014-10-11 HK HK16101922.3A patent/HK1213813A1/zh unknown
- 2014-10-11 JP JP2016521612A patent/JP6463745B2/ja not_active Expired - Fee Related
- 2014-10-11 EP EP14851908.5A patent/EP3056206A4/en not_active Withdrawn
- 2014-10-11 CA CA2926874A patent/CA2926874C/en not_active Expired - Fee Related
- 2014-10-11 NZ NZ718802A patent/NZ718802A/en not_active IP Right Cessation
- 2014-10-13 TW TW103135438A patent/TWI630921B/zh not_active IP Right Cessation
-
2016
- 2016-04-10 IL IL245015A patent/IL245015A0/en unknown
-
2019
- 2019-04-30 US US16/398,827 patent/US20190321369A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3056206A4 (en) | 2017-07-05 |
| JP6463745B2 (ja) | 2019-02-06 |
| IL245015A0 (en) | 2016-05-31 |
| WO2015051763A1 (zh) | 2015-04-16 |
| AU2014334222B2 (en) | 2017-03-09 |
| RU2698796C2 (ru) | 2019-08-30 |
| CA2926874A1 (en) | 2015-04-16 |
| CA2926874C (en) | 2018-12-11 |
| US20190321369A1 (en) | 2019-10-24 |
| AU2014334222A1 (en) | 2016-05-05 |
| NZ718802A (en) | 2017-09-29 |
| EP3056206A1 (en) | 2016-08-17 |
| TW201513894A (zh) | 2015-04-16 |
| RU2016118063A (ru) | 2017-11-16 |
| BR112016007627A2 (pt) | 2017-08-01 |
| JP2016532659A (ja) | 2016-10-20 |
| TWI630921B (zh) | 2018-08-01 |
| US20160235757A1 (en) | 2016-08-18 |
| HK1213813A1 (zh) | 2016-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2535911B (en) | Strigolactone formulations and uses thereof | |
| EP3043824A4 (en) | Modified therapeutic agents and compositions thereof | |
| EP2968474A4 (en) | SKIN COMPOSITIONS AND USES | |
| SG11201508167PA (en) | Therapeutic compositions and uses thereof | |
| SG11201507327TA (en) | Pyrazole-amide compound and medicinal uses therefor | |
| ZA201509307B (en) | Pharmaceutical composition, preparation and uses thereof | |
| PL3064491T3 (pl) | Pochodna sulfonamidowa i jej zastosowanie medyczne | |
| IL276126B (en) | Preparations containing l-4-chloroquinonerine and their uses | |
| EP3007720A4 (en) | COMPOSITION COMPRISING THE GC MACROPHAGE ACTIVATION FACTOR AND USES THEREOF | |
| PL2961481T3 (pl) | Miejscowa, przeciwdrobnoustrojowa kompozycja dermatologiczna | |
| TWI562776B (en) | Pharmaceutical composition and uses thereof | |
| GB201320932D0 (en) | Topical pharmaceutical composition | |
| IL245015A0 (en) | Medicinal composition containing icotinib for topical treatment of the skin and its use | |
| ZA201504604B (en) | Skin care composition | |
| GB201307082D0 (en) | Pharmaceutical composition comprising 15-HETrE and methods of using the same | |
| IL240177A0 (en) | Converted chromium-6-yloxy-cycloalkanes and their use as drugs | |
| PT2992874T (pt) | Lipossoma para administração tópica e aplicação do mesmo | |
| EP3055286A4 (en) | 4-methylsulfonyl-2-butenenitrile and its pharmaceutical use | |
| IL284405A (en) | Pharmaceutical composition, preparation and uses thereof | |
| GB201316498D0 (en) | Topical Pharmaceutical formulation | |
| AU2013901834A0 (en) | Formulations and Therapeutic Uses Thereof | |
| AU2013903132A0 (en) | Compositions for medicinal and cosmetic applications | |
| AU2012900140A0 (en) | Pharmaceutical compositions and topical use thereof |